The pharma industry isn’t lobbying against RFK Jr.’s nomination for a top health role

WASHINGTON — The pharmaceutical industry is not lobbying senators to stop the confirmation of long-time critic Robert F. Kennedy Jr. to the top health care role in the Trump administration.

RFK Jr., President-elect Trump’s pick to run the Department of Health and Human Services, has lambasted the pharmaceutical industry and spread discredited ideas about vaccines.

He’s accused drugmakers of masterminding “mass poisoning” of Americans to make them sicker for profit, of spending vast sums of money to control regulatory agencies and media organizations, and of conspiring with federal agencies to undermine alternative treatments for Covid-19. He threatened to “prosecute and jail the perpetrators” of “pharma corruption,” specifically pointing to Pfizer. He claimed President Trump engaged in “legalized bribery” tied to the pharma industry during his first presidency and appointed “pharma shills high in his administration.” 

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In